SCHEMBL25368136

SCHEMBL25368136

c1ccc(COc2ccc(-c3ccc(-n4ncc5ccc(OCc6ccccc6)cc54)cc3)cc2)cc1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CSNK2A2 P19784 1/20 0.50
CSNK2B P67870 1/20 0.50
CSNK2A1 P68400 1/20 0.50
ALOX5 P09917 1/20 0.49
KHK P50053 1/20 0.48
MDM2 Q00987 2/20 0.47
NR3C1 P04150 2/20 0.45
CYP3A4 P08684 1/20 0.45
GSTP1 P09211 2/20 0.45
MCL1 Q07820 2/20 0.44
BCL2 P10415 1/20 0.43
ENPP3 O14638 1/20 0.43
ENPP1 P22413 1/20 0.43
WDR5 P61964 1/20 0.43
NPC1 O15118 2/20 0.43
RAB9A P51151 2/20 0.43
L3MBTL1 Q9Y468 1/20 0.43
MAP4K1 Q92918 1/20 0.42
MEN1 O00255 1/20 0.42
KMT2A Q03164 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29493747 1.00 CSNK2A2 (0.50) CSNK2A2CSNK2BCSNK2A1ALOX5KHK
SCHEMBL27170715 0.89 ALOX5 (0.48) CSNK2A2CSNK2BCSNK2A1ALOX5KHK
SCHEMBL30749625 0.89 ALOX5 (0.48) CSNK2A2CSNK2BCSNK2A1ALOX5KHK
SCHEMBL9112226 0.86 KHK (0.44) CSNK2A2CSNK2BCSNK2A1ALOX5KHK
SCHEMBL13836268 0.79 RAB9A (0.52) ALOX5NR3C1CYP3A4NPC1RAB9A
SCHEMBL31279323 0.75 KHK (0.43) CSNK2A2CSNK2BCSNK2A1KHKMAP4K1
SCHEMBL23711739 0.75 KHK (0.43) CSNK2A2CSNK2BCSNK2A1KHKMAP4K1
SCHEMBL197017 0.72 LMNA (0.72) ALOX5GSTP1MCL1ENPP3ENPP1
SCHEMBL23483029 0.71 LMNA (0.69) ALOX5GSTP1MCL1ENPP3ENPP1
SCHEMBL1096817 0.71 LMNA (0.69) ALOX5GSTP1MCL1ENPP3ENPP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240083853-A1 HSD17B13 INHIBITORS AND USES THEREOF FL2022-001, INC. 2024-03-14 US disclosed
EP-4221701-A1 HSD17B13 INHIBITORS AND USES THEREOF FL2022-001, Inc. (US) 2023-08-09 EP disclosed
WO-2022072491-A1 HSD17B13 INHIBITORS AND USES THEREOF METACRINE, INC. (US) 2022-04-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240083853-A1 HSD17B13 INHIBITORS AND USES THEREOF HSD17B3, HSD17B11, HSD17B1 CSNK2A2 1546/4885CSNK2B 983/4885CSNK2A1 1380/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.